Paulzen, Michael; Schoretsanitis, Georgios; Stegmann, Benedikt et al.
Pharmacokinetic considerations in antipsychotic augmentation strategies: How to combine risperidone with low-potency antipsychoticsPROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY. Bd. 76. 2017 S. 101-106
Schoretsanitis, G.; Haen, E.; Hiemke, C. et al.
Pharmacokinetic differences for risperidone between gendersEUROPEAN NEUROPSYCHOPHARMACOLOGY. Bd. 27. 2017 S. S56-S57
Findling, Robert L.; Robb, Adelaide S.; DelBello, Melissa et al.
Pharmacokinetics and Safety of Vortioxetine in Pediatric PatientsJOURNAL OF CHILD AND ADOLESCENT PSYCHOPHARMACOLOGY. Bd. 27. H. 6. 2017 S. 526-534
Cheung, Y. Whitney; Barco, Stefano; Mathot, Ron A. A. et al.
Pharmacokinetics of dabigatran etexilate and rivaroxaban in patients with short bowel syndrome requiring parenteral nutrition: The PDER PAN studyTHROMBOSIS RESEARCH. Bd. 160. 2017 S. 76-82
Schoretsanitis, G.; Haen, E.; Hiemke, C. et al.
Pharmacokinetics to rediscover psychotropics; the case of risperidoneEUROPEAN NEUROPSYCHOPHARMACOLOGY. Bd. 27. 2017 S. S547-S547
Daiber, Andreas; Di Lisa, Fabio; Ferdinandy, Peter
Pharmacology of oxidative stress: translational opportunitiesBRITISH JOURNAL OF PHARMACOLOGY. Bd. 174. H. 12. 2017 S. 1511-1513
Völlm, Birgit; Stoffers-Winterling, Jutta; Lieb, Klaus
PharmakotherapieDulz, Briken, Kernberg, Rauchfleisch (Hrsg). Handbuch der Antisozialen Persönlichkeitsstörung. Schattauer 2017
Rades, Dirk; Maderer, Annett; Panzner, Annika et al.
Phase I Study of Definitive Radio-chemotherapy with Cisplatin, 5-Fluorouracil and Cetuximab for Unresectable Locally Advanced Esophageal CancerANTICANCER RESEARCH. Bd. 37. H. 5. 2017 S. 2703-2708
Moehler, Markus; Mahlberg, Rolf; Heinemann, Volker et al.
Phase I study of orally administered S-1 in combination with epirubicin and oxaliplatin in patients with advanced solid tumors and chemotherapy-naive advanced or metastatic esophagogastric cancerGASTRIC CANCER. Bd. 20. H. 2. 2017 S. 358-367
Bug, G.; Burchert, A.; Wagner, E-M et al.
Phase I/II study of the deacetylase inhibitor panobinostat after allogeneic stem cell transplantation in patients with high-risk MDS or AML (PANOBEST trial)LEUKEMIA. Bd. 31. H. 11. 2017 S. 2523-2525